Prevention of COVID-19 Lilly in the elderly and antibody effectiveness of up to 80%

Bamlanivimab, a medium-to-moderate COVID-19 targeted at the new coronavirus prickly protein, has been granted emergency use authorization (EUA) by the FDA to treat high-risk patients.
that although several new crown vaccines have been approved for EUA, it will still take weeks for the new crown vaccine to be effective.
and for some older people or patients with suppressed immune systems, their immune systems may not respond adequately to vaccines.
antibodies as a preventive therapy is effective immediately after the drug is given, and is equally effective in the elderly and patients with suppressed immune systems.
In this randomized, double-blind, placebo-controlled Phase 3 clinical trial, 965 subjects (299 nursing home residents and 666 staff) who tested negative for the new coronavirus at baseline were included in the evaluation and analysis of antibody prevention effectiveness.
subjects were randomly treated with 4200 mg bamlanivimab or a placebo.
after 8 weeks of follow-up in all subjects, the frequency of symptomatic COVID-19 in the bamlanivimab treatment group was significantly lower than in the placebo group (odd ratio=0.43, p=0.00021).
in the pre-defined subgroup of nursing home residents, the frequency of symptomatic COVID-19 patients in patients treated with bamlanivimab was also significantly reduced compared to placebo (odd ratio 0.20; p=0.00026).
results showed that residents who received bamlanivimab randomly had an 80 percent lower risk of contracting COVID-19 than those who received a placebo and lived in the same facility.
four of the 299 residents in the prevention group were caused by COVID-19, all of which occurred in the placebo group and none in the bamlanivimab group.
Dr Daniel Skovronsky, Chief Scientific Officer and President of Lilly Research Laboratories, said: "We are very pleased with these positive results, which demonstrate that bamlanivimab can help prevent COVID-19 and significantly reduce the risk of illness among nursing home residents, who are among the most vulnerable members of society.
we look forward to working with regulators to extend the scope of emergency use authorizations (EUA) to prevent the spread of COVID-19 in these facilities.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
: s neutralizing antibody bamlanivimab (LY-CoV555) prevention COVID-19 at nursing homes in the BLAZE-2 trial, reducing risking by up to 80 percent for residents. Retrieved January 21, 2021, from